Madrigal Pharmaceuticals(MDGL) - 2024 Q4 - Annual Results

Financial Performance - Madrigal Pharmaceuticals reported preliminary fourth-quarter 2024 net sales of Rezdiffra™ (resmetirom) in the range of $100 million to $103 million[4] - For the full year 2024, net sales of Rezdiffra™ are estimated to be between $177 million and $180 million[4] - The preliminary financial results are unaudited and subject to adjustment, with final results expected to be announced in February 2025[5] Cash Position - As of December 31, 2024, the company reported approximately $931 million in cash, cash equivalents, restricted cash, and marketable securities[4]